HSV-1 has been well-characterized and engineered as a gene delivery vector both in research and therapy. Three classes of recombinant vectors have been developed based on HSV-1, which include replication-competent viruses, replication-defective viruses and amplicons. The HSV system we have established is based on HSV-1 H129 strain which is originally isolated from a patient. Through genetic engineering and optimization, our HSV system are able to produce high titer viruses allowing high level transgene expression in infected host cells.